NEW YORK (GenomeWeb News) – Hologic said on Thursday that Canadian regulators approved two of the company's assays for the detection of high-risk strains of human papillomavirus.

Health Canada granted medical device licenses to Hologic's Aptima HPV and Aptima HPV 16 18/45 genotype assays. Both assays are in vitro nucleic acid amplification tests for detecting HPV strains that are associated with cervical cancer and precancerous lesions, Hologic said. The assays were approved to run on the company's Tigris instrument.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.